In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer

Abstract: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. In this study, sorafenib-loaded lipid-based nanosuspensions (sorafenib-LNS) were first developed as an intravenous injectable formulation to increase the efficacy of sorafenib against HCC. LNS were used as nanocarriers for sorafenib owing to their desired features in increasing the solubility and dissolution velocity, improving the bioavailability of sorafenib. Sorafenib-LNS were prepared by nanoprecipitation and consisted of spherical particles with a uniform size distribution (164.5 nm, polydispersity index =0.202) and negative zeta potential (−11.0 mV). The drug loading (DL) was 10.55%±0.16%. Sorafenib-LNS showed higher in vitro cytotoxicity than sorafenib against HepG2 cells (P<0.05) and Bel-7402 cells (P<0.05). The in vivo biodistribution, biocompatibility, and antitumor efficacy of sorafenib-LNS were evaluated in H22-bearing liver cancer xenograft murine model. The results showed that sorafenib-LNS (9 mg/kg) exhibited significantly higher antitumor efficacy by reducing the tumor volume compared with the sorafenib oral group (18 mg/kg, P<0.05) and sorafenib injection group (9 mg/kg, P<0.05). Furthermore, the results of the in vivo biodistribution experiments demonstrated that sorafenib-LNS injected into H22 tumor-bearing mice exhibited increased accumulation in the tumor tissue, which was confirmed by in vivo imaging. In the current experimental conditions, sorafenib-LNS did not show significant toxicity both in vitro and in vivo. These results suggest that sorafenib-LNS are a promising nanomedicine for treating HCC.

Keywords: sorafenib, lipid-based nanosuspensions, HCC, distribution, antitumor effect

Introduction
Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor and the third most frequent cause of cancer death worldwide. More than 80% of patients with HCC are diagnosed at advanced stages of the disease and can only receive palliative treatments; therefore, the prognosis is generally poor with a 5-year survival rate of <5%. Sorafenib was approved for treating HCC by the US Food and Drug Administration (FDA) in 2007 based on the survival advantage identified in a clinical trial, and it was recommended as the first-line drug for HCC therapy by the National Comprehensive Cancer Network and the American Association for the Study of Liver Diseases. Sorafenib has become the standard therapeutic regimen for patients with advanced HCC and also for those progressing after locoregional therapy.

Sorafenib is a small multikinase inhibitor that inhibits cell proliferation via inhibiting the Raf/MEK/ERK signaling pathway and prevents angiogenesis via inhibiting vascular endothelial growth factor and platelet-derived growth factors.
factor receptors.\textsuperscript{9} Currently, sorafenib is administered orally, and the recommended dosage is 400 mg twice daily, although dose reduction or temporary discontinuation occurs frequently because of the unavoidable adverse events, such as gastrointestinal irritation (even major bleeding episodes), diarrhea, and hypertension (estimated to occur in roughly 30% of patients).\textsuperscript{10–12} In addition, the clinical use of sorafenib is limited by its low oral bioavailability (~8.43%), owing to its poor aqueous solubility.\textsuperscript{13} Studies have focused on increasing the antitumor efficacy of sorafenib by improving its solubility and developing injectable formulations.\textsuperscript{14,15}

In this context, rapid growth in nanotechnology toward the development of nanomedicine products holds great promise for cancer therapy.\textsuperscript{16,17} Nanomedicines have unique properties, such as high surface-to-volume ratio and favorable physicochemical characteristics.\textsuperscript{18–20} These properties can improve the pharmacokinetics and pharmacodynamics of conventional therapeutics and optimize the efficacy of existing anticancer compounds.\textsuperscript{19} Various types of nanomedicines have been approved by the FDA and the European Medicines Agency, including lipid-based nanocarriers, polymer-based nanocarriers, inorganic nanoparticles (NPs), and nanosuspensions.\textsuperscript{15,19,21,22}

The antitumor efficacy of sorafenib has been improved by using various types of nanocarriers, such as poly(lactic-co-glycolic acid) (PLGA) NPs, polymeric micelles, and microspheres, for efficient sorafenib delivery.\textsuperscript{14,23–25} For example, sorafenib-loaded \(a,b\)-poly(N-2-hydroxyethyl)-DL-aspartamide–ethylenediamine–poly-lactic acid micelles (~120.2 nm) with a drug loading (DL) of ~3.0% were developed by Craparo et al., and biodistribution studies demonstrated that the amount of sorafenib encapsulated in the micelles reaching the liver was substantially greater than that of free sorafenib, indicating increased accumulation of sorafenib in the liver.\textsuperscript{26} Lin et al prepared sorafenib-loaded PLGA NPs that were spherical in shape and 270 nm in size. Sorafenib-PLGA NPs prolonged the circulation of sorafenib considerably and increased its antifibrotic and antiangiogenic effects compared with free sorafenib.\textsuperscript{28} Liu et al\textsuperscript{14} prepared sorafenib-loaded polymeric NPs at a DL of 2.38%±0.04%, and the NPs exhibited a higher antitumor effect than free sorafenib (\(P<0.05\)). These results indicated that sorafenib nanocarriers are promising for HCC treatment (Figure 1).

We have developed nanodrug delivery systems to increase the antitumor efficacy of sorafenib, including polymeric NPs and liposomes.\textsuperscript{14,27} Lipid-based nanosuspensions (LNS) show unique advantages. First, the injectable phospholipids were used as the stabilizer to ensure better biocompatibility than polymeric NPs. Second, nanosuspensions have high drug-loading capacities, allowing a high drug concentration to reach the target sites and solving the problems of low loading capacity and drug leakage that other nanocarriers, such as liposomes, suffer from.\textsuperscript{28} Third, sorafenib has a high lipophilicity (\(\log P=3.8\)); thus, phospholipids are the appropriate stabilizers to ensure great compatibility with sorafenib.\textsuperscript{29} In our previous work, we prepared docetaxel-loaded LNS and N3-O-toluyl-fluorouracil-loaded LNS by high-pressure homogenization, and both exhibited good antitumor activity and better tumor accumulation than the free drug, which suggested that LNS may be a promising drug delivery system for cancer therapy.\textsuperscript{29,30}

In this study, sorafenib-loaded LNS (sorafenib-LNS) were prepared by nanoprecipitation as an intravenous (IV) injectable formulation that we expected would increase the therapeutic efficiency and reduce gastrointestinal irritation. The particle size, zeta potential, and in vitro release properties of sorafenib-LNS were characterized. The in vitro cytotoxicity was tested on HepG2 and Bel-7402 cells using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The in vivo imaging, tissue biodistribution, and antitumor efficacy were evaluated experimentally.

\textbf{Figure 1} Illustration of sorafenib-loaded nanomedicines.
Materials and methods

Chemicals and cell lines

Sorafenib was obtained from Shanghai Biochempartner Co., Ltd. (Shanghai, People’s Republic of China). Injectable soya phosphatidylcholine was supplied by Shanghai Pharmaceutical Co., Ltd. (Shanghai, People’s Republic of China). Nonionic surfactant polysorbate 80 (Tween-80) was purchased from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, People’s Republic of China). MTT was purchased from Solarbio Bioscience & Technology Co., Ltd. (Shanghai, People’s Republic of China). The 1,1′-Diocatadecyl-3,3′,3′-tetramethylindotricarbocyanine iodide (DiR) was purchased from Fanbo Biochemicals Co., Ltd. (Beijing, People’s Republic of China). All reagents, including acetonitrile and methanol, for high-performance liquid chromatography (HPLC) analysis were HPLC grade. All other chemicals and solvents used were analytical reagent grade.

Human HCC cell line (HepG2) and murine HCC cells (H22) were gifts from the Institute of Immunopharmacology and Immunotherapy, Shandong University (Jinan, People’s Republic of China). The human hepatoma cell line Bel-7402 was donated by the Institute of Pharmacochemistry, Shandong University. The use of these cell lines was approved by the review board of the Institute of Pharmacochemistry.

Animals and tumor model

All animal experiments were carried out in compliance with the requirements of the National Act on the Use of Experimental Animals (People’s Republic of China) and were approved by the Experimental Animal Ethical Committee of Shandong University. Female Kunming mice (4–5 weeks old, ~20 g) and rabbits (New Zealand White, 2.5–3.0 kg) were obtained from the Medical Animal Test Center of the New Drugs Evaluation Center, Shandong University. Mice were housed in groups of six to eight, and rabbits were housed in individual cages. The animals were allowed free access to diet and water and were acclimatized for 1 week before experiments.

To obtain the liver cancer xenograft murine model, a cell suspension (0.1 mL, containing $1 \times 10^6$ viable H22 cells) was implanted into the subcutaneous region of the right flanks of the Kunming mice. After inoculation, the tumor growth in each mouse was closely monitored. The individual tumor volume ($V$) was calculated by $V = (W^2 \times L)/2$, where the width ($W$) is the shortest tumor diameter, and the length ($L$) is the longest tumor diameter.

Mice were sacrificed by cervical dislocation, and the rabbits were sacrificed by lethal injection with a sodium pentobarbital solution.

Preparation of sorafenib-LNS

Sorafenib-LNS were prepared by the solvent displacement technique (nanoprecipitation). Soya lecithin was used because of its good biocompatibility and its compatibility with hydrophobic drugs. Briefly, soya lecithin (150 mg) and sorafenib (18 mg) were dissolved in methanol (2 mL) to form the organic phase at room temperature under ultrasonication. Tween-80 (1.5%, w/v) was dissolved in water (20 mL) to obtain the aqueous phase. The organic phase was added dropwise, at a speed of 5 mL/h using a microsyringe pump, to the aqueous phase under mechanical stirring (DC-40; Hangzhou Electrical Engineering Instruments, Hangzhou, People’s Republic of China) at 1,000 rpm in an ice bath. The solution was left at room temperature and then stirred to evaporate the organic solvent, and the obtained sorafenib-LNS were lyophilized to improve the stability. The freshly prepared LNS were dispensed into glass vials, mannitol (5%, w/v) was added as lyoprotectant, and the mixture was frozen at −80°C for 24 hours. The vials were then transferred to a freeze-dryer (ALPHA1-2; Martin Christ Gefriertrocknungsanlagen GmbH, Osterode am Harz, Germany) for 48 hours to obtain the lyophilized sorafenib-LNS powder.

HPLC analysis of sorafenib and drug content

Sorafenib samples were analyzed by reversed-phase HPLC method adapted from Liu et al. An HPLC system (HP1200; Agilent Technologies, Santa Clara, CA, USA) with a ultraviolet (UV) detector set at 264 nm was used. Chromatography was performed on a 4.6×250 mm column packed with 5 µm particles (Venusil XBP C-18; Bonna-Agela Technologies, Tianjin, People’s Republic of China) under ambient temperature. The mobile phase consisted of acetonitrile–0.03% aqueous triethylamine (63:37, v/v). The samples were diluted with methanol and directly injected (20 µL) into the HPLC system without further treatment. The flow rate was 1.0 mL/min. The calibration curve of the peak area against sorafenib concentration was $A = 5,908.5C \pm 737.04$ ($A$ is the peak area and $C$ is the sorafenib concentration; $r=0.9997$) for sorafenib concentration of 0.2–20 µg/mL. The precision, calibration curves, and accuracy were quantified. The drug content in the sorafenib-LNS was measured by the HPLC method described earlier. Sorafenib-LNS (0.01 mL)
and methanol (0.99 mL) were added to an Eppendorf tube, and then the tube was vortexed for 1 minute. The solution was injected into the HPLC system to detect the drug content in sorafenib-LNS. The DL% of sorafenib-LNS was calculated by

$$DL\% = \frac{W_{\text{drug}}}{W_{\text{lipid}} + W_{\text{drug}}} \times 100$$  \hspace{1cm} (1)$$

where $W_{\text{drug}}$ and $W_{\text{lipid}}$ are the weight of the drug analyzed and the weight of the lipid added to the system, respectively.

Characterization of sorafenib-LNS

Particle size and zeta potential analysis
The lyophilized sorafenib-LNS were redispersed with phosphate-buffered saline (PBS) (pH 7.4) before measurement. The particle size and zeta potential of sorafenib-LNS were determined at 25°C by dynamic light scattering and electrophoretic mobility, respectively (Zetasizer Nano ZS 3000 SH; Malvern Instruments, Malvern, UK).

Transmission electron microscopy
Characterization of the external morphology of sorafenib-LNS was determined by transmission electron microscopy (TEM). A drop of freshly prepared sorafenib-LNS was adsorbed on the surface of a copper grid and air-dried. Owing to the poor conductivity of the organic samples, negative staining with a drop of 2% aqueous sodium phosphotungstate for contrast enhancement was performed 2 minutes before TEM measurements.32

In vitro release studies

The in vitro release profile of sorafenib was evaluated by the dialysis bag diffusion technique. PBS (pH = 7.4) was chosen as the release medium, and 1% (w/v) of Tween-80 was added to solubilize the sorafenib in the release medium.33 Cremophor EL–ethanol (1:1, v/v) was used to dissolve sorafenib, which was then diluted with the release medium to the required concentration.14 Typically, sorafenib solution (1 mL) and sorafenib-LNS (final sorafenib concentration, 15 µg/mL) were placed in preswelled dialysis bags with a 8.0–14.0 kDa molecular weight cutoff, and then the bags were placed in 50 mL conical tubes containing the release media (15 mL). The conical tubes were placed in a shaking incubator with a stirring speed of 100 rpm at a temperature of 37°C. At predetermined sampling times, the whole medium was removed and replaced with fresh PBS to maintain sink conditions. The amount of sorafenib released was determined by the HPLC method described earlier. The release rate was calculated by Equation 2, and the results were expressed as the mean ± SD (n=3).

$$\text{Cumulative release rate} \% = \frac{Q}{W} \times 100 = \sum_{i=1}^{n} \frac{C_i \times V_i}{W} \times 100$$  \hspace{1cm} (2)$$

here, $Q_i$ is the accumulated drug release mass, $C_i$ is the drug concentration in the release medium at each time point, $W$ is the total drug content of the release sample, and $V$ is the volume of the release medium.

Preliminary physical stability

Physical stability
The physical stability of the lyophilized LNS was measured at 4°C±2°C and 25°C±2°C. The changes in particle size were recorded over 3 months.

Serum stability study
Lyophilized sorafenib-LNS were redispersed with PBS (pH 7.4) and then were incubated in 20% or 100% serum at 37°C for 0 hour, 1 hour, 2 hours, 4 hours, 10 hours, 12 hours, 26 hours, 36 hours, 48 hours, and 60 hours. The serum stability was monitored by measuring the particle size distribution.

In vitro cytotoxicity of sorafenib-LNS

Cell culture
HepG2 cell line and Bel-7402 cells were cultured in Roswell Park Memorial Institute 1640 media in a 25 cm² culture flask. The media were supplemented with 10% (v/v) fetal bovine serum and 1% penicillin/streptomycin. The cells were cultured at 37°C under 5% CO₂.

Analysis of in vitro cytotoxicity

Cell growth inhibition efficiency was assessed on HepG2 and Bel-7402 cells by MTT assay. Cells were seeded in 96-well plates at a cell density of 7,000 cells per well, followed by growth for 24 hours at 37°C in a cell culture incubator to allow cell attachment. In the next 48 hours, the cells were exposed to the following treatments: 1) different solvent concentrations (Cremophor EL–ethanol, 1:1, v/v), 2) blank-LNS, 3) sorafenib solution (dissolved in Cremophor EL–ethanol, 1:1, v/v, diluted with cell-conditioned medium), and 4) sorafenib-LNS. All preparations were sterilized by filtering through a 0.22 µm sterile filter. The stock solutions were serially diluted with serum-supplemented media with solvent concentrations of 0.0625%, 0.125%, 0.250%, and 0.500%, and the final concentrations of sorafenib were 0.5 µM, 2.5 µM, 5 µM, 10 µM, and 20 µM, respectively.
Blank-LNS were diluted to the corresponding sorafenib-LNS concentrations using the same method. Each concentration was tested in quintuplicate. After 48 hours of incubation, MTT solution (20 µL, 5 mg/mL in PBS) was added to each well and incubated for another 4 hours. The culture medium and excess MTT were removed, dimethyl sulfoxide (DMSO) (150 µL) was used to dissolve internalized purple formazan crystals, and the plate was placed in the oscillating bioreactor and vibrated for 10 minutes to ensure complete dissolution.

The absorbance (Abs) was measured by a microplate reader (Model 680; Bio-Rad Laboratories Inc., Hercules, CA, USA) with a test wavelength of 490 nm and a reference wavelength of 570 nm. All experiments were repeated in triplicate. Untreated cells were taken as control with 100% viability, and cells without MTT were used as a blank to calibrate the spectrophotometer to zero absorbance. Cell viability was calculated according to

\[
\text{Cell viability (\%)} = \frac{\text{Abs (sample)} - \text{Abs (blank)}}{\text{Abs (control)} - \text{Abs (blank)}} \times 100 \tag{3}
\]

A high concentration of alcohol and Cremophor EL can be cytotoxic. To ensure that the cytotoxicity of sorafenib solution was independent of the solvents, the solvents’ concentration was optimized to determine the dilution multiple for sorafenib solution.

**In vivo biodistribution of sorafenib-LNS**

Biodistribution experiments were carried out in Kunming mice, previously inoculated with H22 cells. Both sorafenib-LNS and sorafenib solution (Cremophor EL–ethanol, 1:1, v/v, diluted with normal saline [NS]) were sterilized by filtering through a 0.22 µm sterile filter and administered IV via the tail vein at a dose of 9 mg/kg. The mice were sacrificed by cervical dislocation at predefined time periods (0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, and 10 hours). The tumors, hearts, livers, spleens, lungs, and kidneys were harvested, washed, weighed, and homogenized (T 10 Ultra-Turrax®; IKA® Werke GmbH & Co., Staufen, Germany). Tissue concentrations of sorafenib were determined by reversed-phase HPLC with UV detector.

**In vivo real-time near-infrared fluorophore imaging**

To observe the biodistribution of LNS formulation over time, real-time near infrared fluorophore (NIRF) imaging was used to monitor the particle fate. An NIRF dye, DiR, replaced sorafenib in the formulation. When the tumors reached 200–300 mm³, the mice were administered DiR-loaded LNS (DiR-LNS) (200 µL, DiR concentration: 40 µg/mL) IV via tail vein injection. Free DiR (40 µg/mL) and NS were used as controls. All preparations were sterilized by filtering through a 0.22 µm sterile filter. After 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, and 48 hours, the mice were anesthetized with 10% chloral hydrate (intraperitoneal) and then placed on their back in a light-tight chamber. The real-time NIRF images were taken using an NIRF imaging system (Xenogen IVIS Lumina; Caliper Life Sciences, Waltham, MA, USA) with an indocyanine green filter (excitation at 745 nm and emission at 835 nm) at the time points. The exposure time was 3 seconds. Results were analyzed using the Living Image 3.1 software (Caliper Life Sciences).

**In vivo antitumor efficacy evaluation**

The in vivo antitumor efficacy evaluation was carried out in H22 tumor-bearing Kunming mice. The tumors grew to a volume of ~100 mm³ 5–8 days after inoculation. Mice were randomly divided into the following four groups (n=6 per group): 1) NS, 2) sorafenib solution (Cremophor EL–ethanol, 1:1, v/v, diluted with NS, 18 mg/kg, oral), 3) sorafenib solution (Cremophor EL–ethanol 1:1, v/v, diluted with NS, 9 mg/kg, IV, and 4) sorafenib-LNS (9 mg/kg, IV). All preparations were sterilized by filtering through a 0.22 µm sterile filter. Mice were administered the appropriate preparation every 3 days for 3 weeks. The average tumor sizes were evaluated using a Vernier caliper to monitor the antitumor efficacy; animals were weighed on alternate days to ascertain possible systemic toxicity. In addition, the tumor volume treatment-to-control (T/C) ratio was also used to estimate the antitumor efficacy and was calculated with

\[
\frac{V_t (\text{end})}{V_c (\text{end})} / \frac{V_t (\text{initial})}{V_c (\text{initial})} \times 100\% \tag{4}
\]

\(V_t\) and \(V_c\) are the median values of tumor volume for the treatment group and the control group (NS), respectively, and (initial) and (end) indicate the volumes at the beginning and end of the treatment, respectively. At the end of the treatment period, mice were sacrificed, the tumors were excised for comparison, and the tumors’ weights were measured.

**Histological observations**

Female Kunming mice (18–22 g) were injected with NS, blank-LNS, and sorafenib-LNS (9 mg/kg) through the tail vein every 3 days. All preparations were sterilized by filtering
through a 0.22 µm sterile filter. Three weeks later, the animals were sacrificed, and the organs (hearts, livers, spleens, lungs, and kidneys) were dissected and washed with NS. The organs were treated with formalin, paraffin embedded, and sectioned. The sections were then stained with hematoxylin and eosin for histopathological examination.

**In vivo vascular irritation study**

The vascular irritation potential of the treatments was evaluated in the ear marginal veins of rabbits. Six rabbits (2.0–2.5 kg) were randomly divided into two groups (group A and group B). The rabbits in group A received sorafenib solution (Cremophor EL–ethanol, 1:1, v/v, diluted with NS), whereas those in group B received sorafenib-LNS at a dosage of 3.2 mg/kg. Accurate volumes of the treatments were injected through the marginal veins of the right ears at a rate of 2 mL/min. As the control treatment, NS was injected into the left ear marginal vein. All injections were performed once a day for five consecutive days. The rabbits were killed 2 days after the last administration, and two parts of the ear vein were obtained for observation, including the regions 1 cm (proximal region) and 2 cm (distal region) from the pinprick. Histopathological examination was performed blindly to evaluate their possible irritation, such as thrombosis, necrosis, and hemorrhage.

**Hemocompatibility assay**

Hemocompatibility studies are important for evaluating the safety of IV preparations. In the hemolysis assay, fresh rat blood was collected and stirred to remove the fibrous protein from the blood. Red blood cells (RBCs) were separated from plasma by centrifugation, washed with saline, and resuspended at a 2% (v/v) cell concentration. The RBC suspension was mixed with sorafenib-LNS. Deionized water was added for the negative control group. After incubation at 37°C for 3 hours, the mixture was centrifuged at 3,000 rpm for 10 minutes to precipitate erythrocytes. The supernatant was collected and analyzed for released hemoglobin with a UV/visible spectrophotometer at 576 nm as an indication of RBC lysis. The hemolysis ratio (HR%) was calculated according to

\[
HR(\%) = \frac{A_{\text{sample}} - A_{\text{negative}}}{A_{\text{positive}} - A_{\text{negative}}} \times 100
\]

where, \(A_{\text{sample}}, A_{\text{negative}}\) and \(A_{\text{positive}}\) are the absorbances of the samples, negative control, and positive control, respectively.

**Use of sorafenib solution**

In this pharmacodynamic evaluation, the reasons for selecting sorafenib solution (Cremophor EL–ethanol, 1:1, v/v, diluted in PBS) rather than a commercial product as the control were as follows: 1) sorafenib is currently clinically available in oral tablet formulation, but it is difficult for mice to swallow pills; 2) the dosage for mice is much less than the drug content of each tablet; thus, it is hard to ensure accurate dosage; and 3) Cremophor EL–ethanol mixture (1:1, v/v) was used to dissolve sorafenib because it is already used to overcome the low aqueous solubility of paclitaxel clinically, and this formulation is commercially available as Taxol®, which was approved by FDA for the treatment of breast cancer in 1992.

**Statistics analysis**

All studies were repeated at least three times. All experimental data were expressed as the mean ± SD. Statistical differences were evaluated with Student’s t-test (Excel 2003; Microsoft Corporation, Redmond, WA, USA). Differences were considered to be statistically significant when the \(P\)-values were <0.05.

**Results and discussion**

**Characterization of sorafenib-LNS**

Sorafenib-LNS were prepared by nanoprecipitation, and the optimal formulation was determined (Figure 2). The nanoparticles after redispersion were pale blue and semitransparent, indicating that sorafenib-LNS were nanosized. The DL of sorafenib-LNS (10.55%±0.16%) was high. The mean particle size and polydispersity index of the three batches of sorafenib-LNS were 164.5±4.5 nm and 0.202±0.015, respectively (Figure 2A), demonstrating that the production method is feasible and stable. Particles <200 nm in size can cause extravasation from microvessels and interstitial transport in tumor tissue via the enhanced permeation and retention (EPR) effect. Therefore, sorafenib-LNS with a size of 164.5 nm were suitable for tumor-targeted drug delivery. In addition, the morphology of sorafenib-LNS was visualized by TEM (Figure 2B). Sorafenib-LNS were well dispersed as individual nearly spherical particles. The average zeta potential for sorafenib-LNS was −11.0±0.28 mV.

**In vitro release studies**

In vitro release of sorafenib-LNS was investigated by the dialysis bag diffusion technique. The amount of released sorafenib was determined by HPLC as described earlier. As shown in Figure 3, the cumulative release percentage of sorafenib from sorafenib-LNS within 5 hours was ~30%, and the relatively quick release rate was caused by the large
surface area-to-volume ratio of LNS. Thereafter, 45.75% of the sorafenib was released within the initial 48 hours. This sustained release could mainly result from the gradual dissolution of the lipid skeleton of the LNS. In contrast, the cumulative release percentage of sorafenib from sorafenib solution was 34.53%, which is significantly lower than that of sorafenib-LNS, indicating the poor water solubility of sorafenib and the necessity of the effective delivery of sorafenib.

Preliminary physical stability

Physical stability

The physical stability of lyophilized sorafenib-LNS was evaluated over 3 months at 4°C±2°C and 25°C±2°C. During this storage period, the appearance and particle size did not change substantially, indicating that the stability of the lyophilized product was good.

Serum stability study

The stability of sorafenib-LNS was evaluated in serum at 37°C. As shown in Figure 4, sorafenib-LNS in 20% and 100%
serum underwent similar particle size and polydispersity index changes within 60 hours. Although the particle sizes changed, sorafenib-LNS were still in the desired ranges for IV injection.

**In vitro cytotoxicity assay**

The in vitro cytotoxicity assay was performed on HepG2 and Bel-7402 cells by the MTT assay for 48 hours at 37°C. The cell viability for different agents is shown in Figure 5, and the half-maximal inhibitory concentration (IC$_{50}$) is presented in Table 1. The solvents (Cremophor EL–ethanol) showed concentration-dependent growth inhibition in both cell lines, and no cytotoxicity observed at the concentration 0.0625% (Figure 5A). Thus, 0.0625% Cremophor EL–ethanol (1:1, v/v) was used to dissolve sorafenib, so that the cytotoxicity of sorafenib solution was not affected by the solvent. The cellular survival rates of the blank-LNS group were >95% at the experimental dosages in these cells (Figure 5B), indicating the good safety and biocompatibility of blank-LNS carriers. In contrast, the cytotoxicity of sorafenib solution and sorafenib-LNS against both cell lines showed dose-dependent changes from

![Figure 5](image-url)  
**Figure 5** Effects of different treatments on cell viabilities (percentage from untreated control) of HepG2 cells and Bel-7402 cells.  
**Notes:** (A) Effect of concentrations of solvents (Cremophor EL–ethanol, 1:1, v/v) on cell viabilities of HepG2 and Bel-7402 cells; (B) effect of blank-LNS on cell viabilities of HepG2 cells and Bel-7402 cells; (C) effect of sorafenib solution (Cremophor EL–ethanol, 1:1, v/v, diluted in PBS) or sorafenib-LNS on cell viabilities of HepG2 cells; and (D) effect of sorafenib solution (Cremophor EL–ethanol, 1:1, v/v, diluted in PBS) or sorafenib-LNS on cell viabilities of Bel-7402 cells. Data are presented as the mean ± SD (n=3). *P<0.05 and **P<0.01.  
**Abbreviations:** blank-LNS, blank lipid-based nanosuspensions; PBS, phosphate-buffered saline; sorafenib-LNS, sorafenib-loaded lipid-based nanosuspensions.

| Cell line | Sorafenib solution ($\mu$M) | Sorafenib-LNS ($\mu$M) |
|-----------|-----------------------------|------------------------|
| HepG2     | 8.61±1.46                   | 3.39±0.56**            |
| Bel-7402  | 10.01±1.11                  | 2.65±0.30**            |

**Table 1** The IC$_{50}$ of sorafenib solution, sorafenib-LNS, and blank-LNS for HepG2 and Bel-7402 cells after 48 hours incubation

**Notes:** The cytotoxicity was tested using the MTT assay, and the sorafenib concentration was 0.5–20 µM. All the data are presented as mean ± SD (n=3; **P<0.01, compared with sorafenib solution).  
**Abbreviations:** blank-LNS, blank lipid-based nanosuspensions; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; sorafenib-LNS, sorafenib-loaded lipid-based nanosuspensions; IC$_{50}$, the half-maximal inhibitory concentration.
In vitro and in vivo antitumor properties of sorafenib-LNS

0.5 µM to 20 µM. There were no significant cytotoxicity differences for sorafenib solution and sorafenib-LNS against HepG2 (Figure 5C) and Bel-7402 cells (Figure 5D) at low concentrations (<2.5 µM), whereas sorafenib-LNS exhibited higher cytotoxicity than sorafenib solution at relative higher concentrations (P<0.01). Furthermore, the IC_{50} value of sorafenib-LNS was significantly lower than that of sorafenib solution (Table 1) in both cell lines (P<0.01). The interaction and intracellular localization could be increased by the lipid components, contributing to the higher in vitro cytotoxicity of sorafenib-LNS. These results suggest that LNS are a promising nanocarrier for improving the in vitro cytotoxicity of sorafenib.

**Time-dependent variation of sorafenib levels in tissues**

The tissue distributions of free sorafenib and sorafenib-LNS were investigated in female Kunming mice following IV administration of sorafenib (9 mg/kg) via the tail vein. Sorafenib was widely distributed in most tissues following IV administration of sorafenib solution (Figure 6). By contrast, the drug concentration in the livers, spleens, and lungs for sorafenib-LNS group was higher than that for the free sorafenib group (Figure 6). This may be because the nanosuspensions had a relatively large mean diameter (164.5±4.48 nm). As submicron particles, LNS could be recognized as foreign bodies in the blood circulation and rapidly cleared by mononuclear phagocyte system cells, which are abundant in special tissues and organs, such as the liver, lung, and spleen. Similar results have been reported in other studies. After administration of sorafenib-LNS formulation, sorafenib was accumulated in liver to a considerable extent compared with other organs. The passive targeting of sorafenib-LNS to liver indicates the potential for an increased therapeutic effect on HCC and requires further investigation.

Moreover, the sorafenib-LNS group showed a substantial accumulation of sorafenib in the tumor, which was significantly larger than in the free sorafenib group (Table 2 and Figure 7). The overall targeting efficiency of LNS in the tumor was increased from 5.96% (free sorafenib) to 7.28% (1.22 times), and the relative targeting efficiency and the maximum concentrations in the tumor were 2.26 and 1.67, respectively.

**Table 2** Targeting disposition of sorafenib after intravenous administration of free sorafenib and sorafenib-LNS to mice (n=3)

| Organs   | Free sorafenib | Sorafenib-LNS |
|----------|----------------|---------------|
|          | Te (%)         | Te (%)        | re          | Ce          |
| Heart    | 12.35±0.85     | 6.09±0.18     | 0.95±0.06   | 0.82±0.07   |
| Liver    | 22.71±0.77     | 42.39±1.85    | 3.60±0.21   | 1.75±0.02   |
| Spleen   | 17.34±1.25     | 15.93±1.32    | 1.78±0.19   | 1.35±0.12   |
| Lung     | 17.15±0.84     | 15.38±1.15    | 1.72±0.15   | 1.54±0.11   |
| Kidney   | 24.50±0.52     | 12.93±0.96    | 1.02±0.09   | 0.89±0.05   |
| Tumor    | 5.96±0.34      | 7.28±1.04     | 2.26±0.27   | 1.67±0.28   |

*Note: All the data are presented as mean ± SD.*

*Abbreviations: Ce, maximum concentration; sorafenib-LNS, sorafenib-loaded lipid-based nanosuspensions; re, relative efficiency; Te, targeting efficiency.*

---

**Figure 6** Mean tissue concentrations of sorafenib after a single IV injection in mice.

*Notes: (A) Mean tissue concentrations of sorafenib after a single IV injection of sorafenib solution (Cremophor EL–ethanol, 1:1, v/v, diluted with normal saline) in mice and (B) mean tissue concentrations of sorafenib after a single IV injection of sorafenib-LNS in mice. Data are presented as the mean ± SD (n=3).*

*Abbreviations: IV, intravenous; sorafenib-LNS, sorafenib-loaded lipid-based nanosuspensions.*
respectively. The tumor accumulation property was further verified in the in vivo imaging study.

**In vivo real-time imaging**

To investigate the in vivo real-time biodistribution and tumor targeting properties of the LNS, the LNS were loaded with NIRF dye, DiR, and then injected into Kunming mice-bearing subcutaneous H22 tumors. Mice were imaged at the predetermined time points with NIRF imaging system. NIRF signals from the free DiR groups of mice were much lower than the signals from the DiR-LNS over the whole period (Figure 8). Nonspecific biodistribution of fluorescence signals was detected for free DiR groups, and no DiR signal was observed in the tumors at the time points except at 2 hours. By contrast, after administration, the DiR-LNS began to accumulate in the tumor and showed stronger NIRF signals in the tumor. The signals were still visible at 48 hours postinjection, indicating increased accumulation of DiR-LNS in the tumor. This higher tumor targeting property of LNS may arise from the prolonged circulation of the LNS in the blood and by “passive targeting” based on the EPR effect, where the accumulation of NPs in solid tumors relies on the blood circulation and extravasation.

The tumor accumulation of LNS is clear in the imaging study rather than in the biodistribution study. Similar results were reported in the study of Hollis et al and Zhao et al. The differences between the fluorescent dye and the drug in the biodistribution indicate that using optical imaging to

---

**Figure 7** Distribution of sorafenib in liver and tumor tissues after IV administration of sorafenib or sorafenib-LNS to mice.

**Notes:** (A) Distribution of sorafenib in liver after IV administration of sorafenib or sorafenib-LNS to mice and (B) distribution of sorafenib in tumor tissues after IV administration of sorafenib or sorafenib-LNS to mice. Data are presented as the mean ± SD (n=3). *P<0.05; **P<0.01.

**Abbreviations:** IV, intravenous; sorafenib-LNS, sorafenib-loaded lipid-based nanosuspensions.

---

**Figure 8** Real-time NIRF images of H22 tumor-bearing mice post-IV injection of free DiR and DiR-LNS.

**Notes:** At 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, and 48 hours postadministration, mice were anesthetized with 10% chloral hydrate (IP) and then placed on their back in a light-tight chamber. The real-time NIRF images were taken using the Xenogen IVIS Lumina system with an ICG filter (excitation at 745 nm and emission at 835 nm). The tumors are circled in red.

**Abbreviations:** DiR, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine iodide; DiR-LNS, DiR-loaded lipid-based nanosuspensions; ICG, indocyanine green; IP, intraperitoneal; IV, intravenous; NIRF, near-infrared fluorophore.
determine the drug distribution may be limited and misleading. This is because of the limitation of light penetration of the NIRF imaging system and the variation in the physicochemical properties of the two molecules.\(^{16}\)

**In vivo antitumor efficacy study**

In vivo antitumor efficacy of sorafenib-LNS on tumor growth was investigated in H22-bearing Kunming mice. Figure 9A illustrates the experimental procedure. The oral sorafenib dosage was twice that of the injection groups, because of the lower oral bioavailability of sorafenib. After 21 days postadministration, the average tumor volumes of mice treated with NS reached \(-1,300 \text{ mm}^3\) (Figure 9B). For the sorafenib-LNS formulation, the average tumor volume was \(<300 \text{ mm}^3\), which was significantly smaller than that of the sorafenib solution injection group (9 mg/kg) \((P<0.05)\) and of the

\[\text{Figure 9} \quad \text{Antitumor efficacy of sorafenib in different formulations in H22 tumor-bearing mice \((n=5)\).} \]

\[\text{Notes:} \quad \text{(A) Schematic of in vivo pharmacodynamic experiments in Kunming mice implanted with H22 tumor cells; (B) time-dependent tumor growth profile of tumor-bearing mice administrated with NS, sorafenib solution (18 mg/kg, oral), sorafenib solution (9 mg/kg, IV), and sorafenib-LNS (9 mg/kg, IV); (C) excised tumor images after tumor therapy; (D) tumor weights after the administration of different formulations; and (E) body weight change after the administration of different formulations in H22 tumor-bearing mice. Data are presented as the mean \pm SD \((n=6)\).} \quad *P<0.05 \text{ and } **P<0.01.\]

\[\text{Abbreviations: IV, intravenous; NS, normal saline; sorafenib-LNS, sorafenib-loaded lipid-based nanosuspensions; sc, subcutaneous injection.}\]
sorafenib solution oral group at double dosage of sorafenib (18 mg/kg) \((P<0.05)\). These differences were reflected in the T/C ratios of tumor volume. For sorafenib-LNS, sorafenib solution (IV), and sorafenib solution (oral), the tumor volume T/C ratios were 29.4%, 35.2%, and 51.2%, respectively. At the end of the experiment, the animals were sacrificed, and then the solid tumors were dissected, weighed, and compared. As expected, the tumors in sorafenib-LNS group were much smaller than those in the other groups (Figure 9C). The tumor weight in mice after treatment with sorafenib-LNS was 0.25±0.06 g, which was significantly smaller than that of the sorafenib solution oral group \((P<0.01)\) and of the sorafenib solution injection group \((P<0.01)\) (Figure 9D). Overall, these results demonstrated that sorafenib-LNS exhibited better anticancer efficacy in vivo in murine liver cancer model, which was consistent with the in vitro cytotoxicity test results. These results could be explained as follows. First, compared with the oral group, IV sorafenib-LNS retained 100% bioavailability.\(^4\) Second, sorafenib-LNS accumulated in the tumor tissue through the EPR effect, maintaining the effective therapeutic concentration for a longer period of time.\(^4\) This increased tumor accumulation property was supported by the biodistribution and imaging studies.

The body weight changes of the mice were monitored as an index of systemic toxicity. As shown in Figure 9E, body weights of the mice in sorafenib-LNS group showed a stable increase rate during the treatment, indicating the lower systemic toxicity of sorafenib-LNS.\(^5\)

### In vivo vascular irritation study

The rabbit vein irritation test was performed to evaluate the vascular irritation potential of sorafenib-LNS, with a solution of sorafenib as the reference and NS as the negative control. The histopathological examination results (Figure 10) showed no observable changes, such as erythrocyte aggregation and inflammatory cell infiltration, at or away from the injection site following the administration of sorafenib solution, sorafenib-LNS, or NS. In addition, none of the groups showed pathological changes, such as thrombosis, necrosis, and hemorrhage, indicating that sorafenib-LNS treatment did not cause IV irritation.

### Toxicological analysis

To further confirm the safety of the formulation, histological observation of tissues exposed to blank-LNS and sorafenib-LNS was performed to determine whether or not LNS caused tissue damage, inflammation, or lesions. The cytoarchitecture of the tissue showed no obvious differences (eg, necrosis) between the LNS formulation and the placebo (Figure 11). The results indicated that both the blank-LNS and sorafenib-LNS formulations showed minor toxicity.

### Hemolysis assay

The hemolytic activity of sorafenib-LNS was low and negligible (<5%), within a range of 10–50 µg/mL (Figure 12A). Generally, a hemolysis percentage of <5% is regarded as nontoxic and safe.\(^5\) In addition, no hemolysis or aggregation

---

**Figure 10** Photomicrographs of pathological sections of rabbit ear-rim vein after different treatments.

**Notes:** Two parts of the ear vein were obtained for histopathological examination, including the region 1 cm (proximal region) and 2 cm (distal region) from the pinprick.

**Abbreviations:** NS, normal saline; sorafenib-LNS, sorafenib-loaded lipid-based nanosuspensions.
phenomena were observed for the different concentrations of sorafenib-LNS (Figure 12B). These results indicated that sorafenib-LNS had good hemocompatibility under preliminary experimental conditions, and they were suitable for IV administration.

**Conclusion**

In this study, sorafenib-LNS were successfully prepared by nanoprecipitation and showed several attractive features as a drug delivery system, such as spherical particles, uniform size distribution, and sustained drug release. The appropriate particle size of sorafenib-LNS favored the EPR effect, and the narrow particle size distribution ensured the stability of the suspension. In the cytotoxicity activity analysis, sorafenib-LNS showed higher cytotoxicity than sorafenib solution against both HepG2 cells and Bel-7402 cells, and the superiority was further reflected in in vivo pharmacodynamic evaluation. In H22-bearing Kunming mice, sorafenib-LNS (9 mg/kg) exhibited higher antitumor efficacy than the sorafenib oral group (18 mg/kg) ($P<0.05$) and the sorafenib injection group (9 mg/kg) ($P<0.05$). In vivo imaging and biodistribution experiments demonstrated that sorafenib-LNS achieved significant accumulation in tumors. The in vivo vascular irritation study, hemolysis assay, and the normal cytoarchitecture of the tissue in the histopathological study indicated the good
The biocompatibility of sorafenib-LNS in vivo. These results suggest that sorafenib-LNS effectively inhibit tumor growth and provide a promising approach for IV administration of sorafenib. Moreover, the study laid the groundwork for further investigation of LNS for the co-delivery of sorafenib-based combination.

Acknowledgments

This work was supported by the Science and Technology Development Project of Shandong Province (2014GSF121032) and the Independent Innovation Foundation of Shandong University (2015GN019).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245–1255.
2. Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol. 2010;80(5):550–560.
3. Bertino G. Hepatocellular carcinoma: present and future. Chin Clin Oncol. 2012;1(1):14.
4. DiFrancesco C [webpage on the Internet]. FDA Approves Nexavar for Patients with Inoperable Liver Cancer; 2007. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109030.htm. Accessed April 14, 2016.
5. Benson AB 3rd, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7(4):350–391.
6. Llovet JM, Di Biscaglia AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008; 100(10):698–711.
7. Leoni S, Piscaglia F, Serio I, et al. Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. Dig Liver Dis. 2014; 46(6):549–555.
8. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48(4):1312–1327.
9. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5(10):835–844.
10. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390.
11. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.
12. Mancuso A, Airoldi A, Viganò R, Pinzello G. Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation. Dig Liver Dis. 2011;43(9):754.
13. Zhang Z, Niu B, Chen J, et al. The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer. Biomaterials. 2014;35(15):4565–4572.
14. Liu Y, Feng L, Liu T, et al. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer. Nanoscale. 2014;6(6):3231–3242.
15. Waknine Y [webpage on the Internet]. FDA Approvals: Nascobal Nasal Spray, PTC 124, Tocosol Paclitaxel; 2005. Available from: http://www.medscape.com/viewarticle/498694. Accessed January 12, 2016.
16. Chang EH, Harford JB, Eaton MA, et al. Nanomedicine: past, present and future – a global perspective. Biochem Biophys Res Commun. 2015;468(3):511–517.
17. Cai LT, Sheng ZH. Advances in cancer nanomedicine. Cancer Biol Med. 2015;12(3):141–142.
18. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm. 2011;8(6):2101–2141.
19. Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138–157.
20. Xu X, Ho W, Zhang X, Bertrand N, Farokhzad O. Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol Med. 2015;21(4):223–232.
21. Barratt G, Bretagne S. Optimizing efficacy of Amphotericin B through nanomodification. Int J Nanomedicine. 2007;2(3):301–313.
22. Barenholz Y. Doxil(R) – the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117–134.
23. Wang XQ, Fan JM, Liu YO, Zhao B, Jia ZR, Zhang Q. Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat. Int J Pharm. 2011;419(1–2):339–346.
24. Lin Ts T, Gao DY, Liu YC, et al. Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis. J Control Release. 2016;221:62–70.
25. Shen J, Sun H, Meng Q, et al. Simultaneous inhibition of tumor growth and angiogenesis for resistant hepatocellular carcinoma by co-delivery of sorafenib and survivin small hairpin RNA. Mol Pharm. 2014;11(10):3342–3351.
26. Crapearo EF, Sardo C, Serio R, et al. Galactosylated polymeric carriers for liver targeting of sorafenib. Int J Pharm. 2014;466(1–2):172–180.
27. Yao Y, Su Z, Liang Y, Zhang N. pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery. Int J Nanomedicine. 2015;10:6185–6197.
28. Danhier F, Ucakar B, Vanderhaegen ML, Brewer ME, Arien T, Preot V. Nanosuspension for the delivery of a poorly soluble anti-cancer kinase inhibitor. Eur J Pharm Biopharm. 2014;88(1):252–260.
29. Wang L, Liu Z, Liu D, Liu C, Juan Z, Zhang N. Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity. Int J Pharm. 2011;413(1–2):194–201.
30. Zhang J, Li M, Liu Z, Wang L, Liu Y, Zhang N. Preclinical studies of N(3)-O-toluyl-fluorouracil-loaded lipid-based nanosuspensions in H(2)(2)O-bearing mice. Int J Nanomedicine. 2014;9:2741–2751.
31. Yu W, Liu C, Liu Y, Zhang N, Xu W. Mannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophages. Pharm Res. 2010;27(8):1584–1596.
32. Su Z, Liang Y, Yao Y, et al. Polymeric complex micelles based on the double-hydrazone linkage and dual drug-loading strategy for pH-sensitive docetaxel delivery. J Mater Chem B. 2016;4:1122–1133.
33. Wang L, Li M, Zhang N. Folate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapy. Int J Nanomedicine. 2012;7:3281–3294.
34. Wang M, Liu T, Han L, Gao W, Yang S, Zhang N. Functionalized O-carboxymethyl-chitosan/polyethyleneimine based novel dual pH-responsive nanocarriers for controlled co-delivery of DOX and genes. Polym Chem. 2015;6(17):3324–3335.
35. Yang C, Liu SQ, Venkataraman S, et al. Structure-directing star-shaped block copolymers: supramolecular vesicles for the delivery of anticancer drugs. J Control Release. 2015;208:93–105.
36. Attia AB, Yang C, Tan JP, et al. The effect of kinetic stability on biodistribution and anti-tumor efficacy of drug-loaded biodegradable polymeric micelles. Biomaterials. 2013;34(12):3132–3140.
37. Botella P, Abasolo I, Fernandez Y, et al. Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation. J Control Release. 2011;156(2):246–257.
38. Zarrabi A, Vossoughi M. Paclitaxel/β-CD-g-PG inclusion complex: an insight into complexation thermodynamics and guest solubility. J Mol Liq. 2015;208:145–150.
39. Ali HSM, York P, Ali AMA, Blagden N. Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling. J Control Release. 2011;149(2):175–181.
40. Liu F, Li M, Liu C, et al. Tumor-specific delivery and therapy by double-targeted DTX-CMCS-PEG-NGR conjugates. Pharm Res. 2014;31(2):475–488.
41. Zhang H, Zhang FM, Yan SJ. Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles. Int J Nanomedicine. 2012;7:2901–2910.
42. Rewatkar PV, Parton RG, Parekh HS, Parat MO. Are caveolae a cellular entry route for non-viral therapeutic delivery systems? Adv Drug Deliv Rev. 2015;91:92–108.
43. Gao L, Zhang D, Chen M, et al. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm. 2008;355(1–2):321–327.
44. Peters K, Leitzke S, Diederichs JE, et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother. 2000;45(1):77–83.
45. Wang L, Li M, Zhang N. Folate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapy. Int J Pharm. 2012;7:3281–3293.
46. Hollis CP, Weiss HL, Leggas M, Evers BM, Gemeinhart RA, Li T. Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. J Control Release. 2013;172(1):12–21.
47. Zhao R, Hollis CP, Zhang H, Sun L, Gemeinhart RA, Li T. Hybrid nanocrystals: achieving concurrent therapeutic and bioimaging functionalities toward solid tumors. Mol Pharm. 2011;8(5):1985–1991.
48. Banker GS, Siepmann J, Rhodes C. Modern Pharmaceutics. Boca Raton: Marcel Dekker Press; 2002.
49. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63(3):131–135.
50. Feng LX, Li M, Liu YJ, Yang SM, Zhang N. Synergistic enhancement of cancer therapy using a combination of ceramide and docetaxel. Int J Mol Sci. 2014;15(3):4201–4220.
51. Xiao Y, Liu Y, Yang S, et al. Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment. Colloid Surf B. 2016;141:83–92.